At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Busulfan, Melphalan, and 3 other interventions for DS Stage I Plasma Cell Myeloma and 3 related conditions. Completed, enrolled 19 participants across 4 sites.
Detailed Summary
This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line stem cell transplant works in treating patients with multiple myeloma. Giving chemotherapy before a peripheral blood stem cell transplant may stop the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Undergo autologous PBSCT
Undergo autologous PBSCT